It may appear a bit ambitious for Indian firms to leapfrog straight into cell and gene therapy, bypassing many traditional R&D milestones, but there’s been more than a mere trickle of news on plans underway in the segment, albeit much of it early stage.
Pipeline Includes Tocilizumab, Abatacept
Dr Reddy’s highlighted some key pipeline details on the biosimilars front, as it scales up in the area as part...
At its recent investor day event, Dr. Reddy's Laboratories Ltd. indicated that while scaling up the current biosimilars business (see side box) is a key prong of its "Horizon-1"...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on In Vivo for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?